Management of asymptomatic hyperuricemia: Integrated Diabetes & Endocrine Academy (IDEA) consensus statement
The definition and management of asymptomatic hyperuricemia has been an area of controversy for many decades. Debate persists regarding the benefit of treating all cases of asymptomatic hyperuricemia and hence, unsurprisingly there are no clear clinical practice guidelines from our country. Ten memb...
Gespeichert in:
| Veröffentlicht in: | Diabetes & metabolic syndrome clinical research & reviews 2020-03, Vol.14 (2), p.93-100 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 100 |
|---|---|
| container_issue | 2 |
| container_start_page | 93 |
| container_title | Diabetes & metabolic syndrome clinical research & reviews |
| container_volume | 14 |
| creator | Valsaraj, Rahul Singh, Awadhesh Kumar Gangopadhyay, Kalyan Kumar Ghoshdastidar, Biswajit Goyal, Ghanshyam Batin, Masood Mukherjee, Dibyendu Sengupta, Upal Chatterjee, Sanjay Sengupta, Nilanjan |
| description | The definition and management of asymptomatic hyperuricemia has been an area of controversy for many decades. Debate persists regarding the benefit of treating all cases of asymptomatic hyperuricemia and hence, unsurprisingly there are no clear clinical practice guidelines from our country.
Ten members consisting of eminent physicians, endocrinologists, nephrologist and a rheumatologist were selected by the Integrated Diabetes & Endocrine Academy (IDEA) for a closed meeting with the aim to come to a consensus.
A literature search was performed using PubMed and Cochrane library following which published articles in indexed peer review journals were selected.
Each participant voiced their opinion after reviewing the available data and a consensus was reached after three meetings by voting.
Recommendations were made on important areas such as definition, investigation and management of asymptomatic hyperuricemia.
•There are no clear clinical practice guidelines on management of asymptomatic hyperuricemia from India.•Unnecessary investigation of serum uric acid for all patients with rheumatological symptoms should be discouraged.•Urate lowering therapy are well known for its side effects however, new evidence showing benefit of therapy cannot be ignored.•This consensus statement aims to lay down clear recommendations in the management of asymptomatic hyperuricemia. |
| doi_str_mv | 10.1016/j.dsx.2020.01.007 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2348232918</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1871402120300084</els_id><sourcerecordid>2348232918</sourcerecordid><originalsourceid>FETCH-LOGICAL-c353t-3cacc69a70d8f8c957f352ad1b682b742bcae45b9d958ad6822179532295d88d3</originalsourceid><addsrcrecordid>eNp9kL1u2zAURokgRe0kfYAsAafAGaTyR7TIZjJiNzWQIks7ExR5ldCwKJekgvrtK9dux0y8IM73XdyD0DUlJSV0_nlTuvS7ZISRktCSkPoMTamsZUE4r87_zrSoCKMTdJHShhAhFFMf0YRTpShTaoq2300wL9BByLhvsUn7bpf7zmRv8et-B3GI3kLnzRe8Dhleosng8NKbBjIkfItXwfU2-gB4YY2Dbo9n6-VqcYdtHxKENCSc8hg6bLhCH1qzTfDp9F6in19XPx6-FU_Pj-uHxVNhueC54NZYO1emJk620ipRt1ww42gzl6ypK9ZYA5VolFNCGjd-MlorwRlTwknp-CWaHXt3sf81QMq688nCdmsC9EPSjFeScaaoHFF6RG3sU4rQ6l30nYl7TYk-SNYbPUrWB8maUD1KHjM3p_qh6cD9T_yzOgL3RwDGI988RJ2sh2DB-Qg2a9f7d-r_AJxwjVg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2348232918</pqid></control><display><type>article</type><title>Management of asymptomatic hyperuricemia: Integrated Diabetes & Endocrine Academy (IDEA) consensus statement</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Valsaraj, Rahul ; Singh, Awadhesh Kumar ; Gangopadhyay, Kalyan Kumar ; Ghoshdastidar, Biswajit ; Goyal, Ghanshyam ; Batin, Masood ; Mukherjee, Dibyendu ; Sengupta, Upal ; Chatterjee, Sanjay ; Sengupta, Nilanjan</creator><creatorcontrib>Valsaraj, Rahul ; Singh, Awadhesh Kumar ; Gangopadhyay, Kalyan Kumar ; Ghoshdastidar, Biswajit ; Goyal, Ghanshyam ; Batin, Masood ; Mukherjee, Dibyendu ; Sengupta, Upal ; Chatterjee, Sanjay ; Sengupta, Nilanjan</creatorcontrib><description>The definition and management of asymptomatic hyperuricemia has been an area of controversy for many decades. Debate persists regarding the benefit of treating all cases of asymptomatic hyperuricemia and hence, unsurprisingly there are no clear clinical practice guidelines from our country.
Ten members consisting of eminent physicians, endocrinologists, nephrologist and a rheumatologist were selected by the Integrated Diabetes & Endocrine Academy (IDEA) for a closed meeting with the aim to come to a consensus.
A literature search was performed using PubMed and Cochrane library following which published articles in indexed peer review journals were selected.
Each participant voiced their opinion after reviewing the available data and a consensus was reached after three meetings by voting.
Recommendations were made on important areas such as definition, investigation and management of asymptomatic hyperuricemia.
•There are no clear clinical practice guidelines on management of asymptomatic hyperuricemia from India.•Unnecessary investigation of serum uric acid for all patients with rheumatological symptoms should be discouraged.•Urate lowering therapy are well known for its side effects however, new evidence showing benefit of therapy cannot be ignored.•This consensus statement aims to lay down clear recommendations in the management of asymptomatic hyperuricemia.</description><identifier>ISSN: 1871-4021</identifier><identifier>EISSN: 1878-0334</identifier><identifier>DOI: 10.1016/j.dsx.2020.01.007</identifier><identifier>PMID: 31991299</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Asymptomatic Diseases - therapy ; Humans ; Hyperuricemia ; Hyperuricemia - complications ; Hyperuricemia - diagnosis ; Hyperuricemia - therapy ; Urate lowering therapy ; Uric acid</subject><ispartof>Diabetes & metabolic syndrome clinical research & reviews, 2020-03, Vol.14 (2), p.93-100</ispartof><rights>2020 Diabetes India</rights><rights>Copyright © 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c353t-3cacc69a70d8f8c957f352ad1b682b742bcae45b9d958ad6822179532295d88d3</citedby><cites>FETCH-LOGICAL-c353t-3cacc69a70d8f8c957f352ad1b682b742bcae45b9d958ad6822179532295d88d3</cites><orcidid>0000-0002-8374-4536 ; 0000-0001-9260-2831 ; 0000-0002-2397-6466</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.dsx.2020.01.007$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31991299$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Valsaraj, Rahul</creatorcontrib><creatorcontrib>Singh, Awadhesh Kumar</creatorcontrib><creatorcontrib>Gangopadhyay, Kalyan Kumar</creatorcontrib><creatorcontrib>Ghoshdastidar, Biswajit</creatorcontrib><creatorcontrib>Goyal, Ghanshyam</creatorcontrib><creatorcontrib>Batin, Masood</creatorcontrib><creatorcontrib>Mukherjee, Dibyendu</creatorcontrib><creatorcontrib>Sengupta, Upal</creatorcontrib><creatorcontrib>Chatterjee, Sanjay</creatorcontrib><creatorcontrib>Sengupta, Nilanjan</creatorcontrib><title>Management of asymptomatic hyperuricemia: Integrated Diabetes & Endocrine Academy (IDEA) consensus statement</title><title>Diabetes & metabolic syndrome clinical research & reviews</title><addtitle>Diabetes Metab Syndr</addtitle><description>The definition and management of asymptomatic hyperuricemia has been an area of controversy for many decades. Debate persists regarding the benefit of treating all cases of asymptomatic hyperuricemia and hence, unsurprisingly there are no clear clinical practice guidelines from our country.
Ten members consisting of eminent physicians, endocrinologists, nephrologist and a rheumatologist were selected by the Integrated Diabetes & Endocrine Academy (IDEA) for a closed meeting with the aim to come to a consensus.
A literature search was performed using PubMed and Cochrane library following which published articles in indexed peer review journals were selected.
Each participant voiced their opinion after reviewing the available data and a consensus was reached after three meetings by voting.
Recommendations were made on important areas such as definition, investigation and management of asymptomatic hyperuricemia.
•There are no clear clinical practice guidelines on management of asymptomatic hyperuricemia from India.•Unnecessary investigation of serum uric acid for all patients with rheumatological symptoms should be discouraged.•Urate lowering therapy are well known for its side effects however, new evidence showing benefit of therapy cannot be ignored.•This consensus statement aims to lay down clear recommendations in the management of asymptomatic hyperuricemia.</description><subject>Asymptomatic Diseases - therapy</subject><subject>Humans</subject><subject>Hyperuricemia</subject><subject>Hyperuricemia - complications</subject><subject>Hyperuricemia - diagnosis</subject><subject>Hyperuricemia - therapy</subject><subject>Urate lowering therapy</subject><subject>Uric acid</subject><issn>1871-4021</issn><issn>1878-0334</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kL1u2zAURokgRe0kfYAsAafAGaTyR7TIZjJiNzWQIks7ExR5ldCwKJekgvrtK9dux0y8IM73XdyD0DUlJSV0_nlTuvS7ZISRktCSkPoMTamsZUE4r87_zrSoCKMTdJHShhAhFFMf0YRTpShTaoq2300wL9BByLhvsUn7bpf7zmRv8et-B3GI3kLnzRe8Dhleosng8NKbBjIkfItXwfU2-gB4YY2Dbo9n6-VqcYdtHxKENCSc8hg6bLhCH1qzTfDp9F6in19XPx6-FU_Pj-uHxVNhueC54NZYO1emJk620ipRt1ww42gzl6ypK9ZYA5VolFNCGjd-MlorwRlTwknp-CWaHXt3sf81QMq688nCdmsC9EPSjFeScaaoHFF6RG3sU4rQ6l30nYl7TYk-SNYbPUrWB8maUD1KHjM3p_qh6cD9T_yzOgL3RwDGI988RJ2sh2DB-Qg2a9f7d-r_AJxwjVg</recordid><startdate>202003</startdate><enddate>202003</enddate><creator>Valsaraj, Rahul</creator><creator>Singh, Awadhesh Kumar</creator><creator>Gangopadhyay, Kalyan Kumar</creator><creator>Ghoshdastidar, Biswajit</creator><creator>Goyal, Ghanshyam</creator><creator>Batin, Masood</creator><creator>Mukherjee, Dibyendu</creator><creator>Sengupta, Upal</creator><creator>Chatterjee, Sanjay</creator><creator>Sengupta, Nilanjan</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8374-4536</orcidid><orcidid>https://orcid.org/0000-0001-9260-2831</orcidid><orcidid>https://orcid.org/0000-0002-2397-6466</orcidid></search><sort><creationdate>202003</creationdate><title>Management of asymptomatic hyperuricemia: Integrated Diabetes & Endocrine Academy (IDEA) consensus statement</title><author>Valsaraj, Rahul ; Singh, Awadhesh Kumar ; Gangopadhyay, Kalyan Kumar ; Ghoshdastidar, Biswajit ; Goyal, Ghanshyam ; Batin, Masood ; Mukherjee, Dibyendu ; Sengupta, Upal ; Chatterjee, Sanjay ; Sengupta, Nilanjan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c353t-3cacc69a70d8f8c957f352ad1b682b742bcae45b9d958ad6822179532295d88d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Asymptomatic Diseases - therapy</topic><topic>Humans</topic><topic>Hyperuricemia</topic><topic>Hyperuricemia - complications</topic><topic>Hyperuricemia - diagnosis</topic><topic>Hyperuricemia - therapy</topic><topic>Urate lowering therapy</topic><topic>Uric acid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Valsaraj, Rahul</creatorcontrib><creatorcontrib>Singh, Awadhesh Kumar</creatorcontrib><creatorcontrib>Gangopadhyay, Kalyan Kumar</creatorcontrib><creatorcontrib>Ghoshdastidar, Biswajit</creatorcontrib><creatorcontrib>Goyal, Ghanshyam</creatorcontrib><creatorcontrib>Batin, Masood</creatorcontrib><creatorcontrib>Mukherjee, Dibyendu</creatorcontrib><creatorcontrib>Sengupta, Upal</creatorcontrib><creatorcontrib>Chatterjee, Sanjay</creatorcontrib><creatorcontrib>Sengupta, Nilanjan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes & metabolic syndrome clinical research & reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Valsaraj, Rahul</au><au>Singh, Awadhesh Kumar</au><au>Gangopadhyay, Kalyan Kumar</au><au>Ghoshdastidar, Biswajit</au><au>Goyal, Ghanshyam</au><au>Batin, Masood</au><au>Mukherjee, Dibyendu</au><au>Sengupta, Upal</au><au>Chatterjee, Sanjay</au><au>Sengupta, Nilanjan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Management of asymptomatic hyperuricemia: Integrated Diabetes & Endocrine Academy (IDEA) consensus statement</atitle><jtitle>Diabetes & metabolic syndrome clinical research & reviews</jtitle><addtitle>Diabetes Metab Syndr</addtitle><date>2020-03</date><risdate>2020</risdate><volume>14</volume><issue>2</issue><spage>93</spage><epage>100</epage><pages>93-100</pages><issn>1871-4021</issn><eissn>1878-0334</eissn><abstract>The definition and management of asymptomatic hyperuricemia has been an area of controversy for many decades. Debate persists regarding the benefit of treating all cases of asymptomatic hyperuricemia and hence, unsurprisingly there are no clear clinical practice guidelines from our country.
Ten members consisting of eminent physicians, endocrinologists, nephrologist and a rheumatologist were selected by the Integrated Diabetes & Endocrine Academy (IDEA) for a closed meeting with the aim to come to a consensus.
A literature search was performed using PubMed and Cochrane library following which published articles in indexed peer review journals were selected.
Each participant voiced their opinion after reviewing the available data and a consensus was reached after three meetings by voting.
Recommendations were made on important areas such as definition, investigation and management of asymptomatic hyperuricemia.
•There are no clear clinical practice guidelines on management of asymptomatic hyperuricemia from India.•Unnecessary investigation of serum uric acid for all patients with rheumatological symptoms should be discouraged.•Urate lowering therapy are well known for its side effects however, new evidence showing benefit of therapy cannot be ignored.•This consensus statement aims to lay down clear recommendations in the management of asymptomatic hyperuricemia.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>31991299</pmid><doi>10.1016/j.dsx.2020.01.007</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-8374-4536</orcidid><orcidid>https://orcid.org/0000-0001-9260-2831</orcidid><orcidid>https://orcid.org/0000-0002-2397-6466</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1871-4021 |
| ispartof | Diabetes & metabolic syndrome clinical research & reviews, 2020-03, Vol.14 (2), p.93-100 |
| issn | 1871-4021 1878-0334 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2348232918 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Asymptomatic Diseases - therapy Humans Hyperuricemia Hyperuricemia - complications Hyperuricemia - diagnosis Hyperuricemia - therapy Urate lowering therapy Uric acid |
| title | Management of asymptomatic hyperuricemia: Integrated Diabetes & Endocrine Academy (IDEA) consensus statement |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T12%3A03%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Management%20of%20asymptomatic%20hyperuricemia:%20Integrated%20Diabetes%20&%20Endocrine%20Academy%20(IDEA)%20consensus%20statement&rft.jtitle=Diabetes%20&%20metabolic%20syndrome%20clinical%20research%20&%20reviews&rft.au=Valsaraj,%20Rahul&rft.date=2020-03&rft.volume=14&rft.issue=2&rft.spage=93&rft.epage=100&rft.pages=93-100&rft.issn=1871-4021&rft.eissn=1878-0334&rft_id=info:doi/10.1016/j.dsx.2020.01.007&rft_dat=%3Cproquest_cross%3E2348232918%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2348232918&rft_id=info:pmid/31991299&rft_els_id=S1871402120300084&rfr_iscdi=true |